Ticker brief
HUMA HUMACYTE INC
Consumer, Non-cyclical · Biotechnology
last close
$0.4354
1 day
+5.4%
14 days
+7.4%
mkt cap
$191.4M
signals 14d
15
authors 14d
5
crowd 14d
+0.7σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 131% mid · 47 pctile own 1y | IV/HV 1.56× (as of 2025-10-29) |
| Skew — 25Δ RR 30d | +0.212 86 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +1.62 elevated | 5-session Δ +0.96 (as of 2025-10-29) |
| OI alarm | quiet | last alarm 2025-10-08 (z=2.3) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-11 → 2026-10-16 · now +0.32 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PolarizingLit | C | -0.26 | 4 | +0.37 |
| @PrismMarketView | C | · | 4 | +0.24 |
| @BiopharmIQ | B | · | 4 | +0.24 |
| @Analytica_X | B | -0.29 | 2 | +0.42 |
| @PrismDM | A | -2.76 | 1 | +0.05 |
Recent signals15of 15 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @PolarizingLit | +0.20 | Notes that HUMA is the author's only positive holding for the day. | +1.5% | tweet ↗ |
| 2026-10-16 | @PrismMarketView | +0.25 | Presents four public companies as a trauma-care innovation basket. | +1.5% | tweet ↗ |
| 2026-10-16 | @Analytica_X | +0.45 | Reports session gains across five speculative small-cap securities. | +1.5% | tweet ↗ |
| 2026-10-16 | @Analytica_X | +0.40 | Highlights strong gains in biotechnology, mining and related small-cap names. | +1.5% | tweet ↗ |
| 2026-10-15 | @PrismMarketView | +0.45 | Reports 44% quarterly growth in hospitals ordering Symvess. | -0.9% | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | +0.40 | The tweet lists large opening biotech moves and upcoming Phase 3 catalysts. | -0.9% | tweet ↗ |
| 2026-10-15 | @BiopharmIQ | +0.40 | The post lists major opening biotech gains and the news associated with each move. | -0.9% | tweet ↗ |
| 2026-10-15 | @PolarizingLit | +0.45 | Reports increased surgeon use of HUMA's bioengineered human tissue. | -0.9% | tweet ↗ |
| 2026-10-14 | @PrismMarketView | +0.10 | Highlights three emergency-care medical technology companies. | +23.0% | tweet ↗ |
| 2026-10-13 | @PolarizingLit | +0.65 | Expresses optimism about HUMA's regenerative potential and notes an October 22 dialysis-data presentation. | +21.3% | tweet ↗ |
| 2026-10-12 | @BiopharmIQ | +0.35 | Frames HUMA as overlooked despite positive Phase 3 data and a planned November filing. | +11.8% | tweet ↗ |
| 2026-10-12 | @BiopharmIQ | -0.20 | Summarizes same-day biotech price reactions to clinical catalysts. | +11.8% | tweet ↗ |
| 2026-10-12 | @PrismDM | +0.05 | Humacyte scheduled interim Phase 3 data for October 22 and targets an sBLA filing in Q4. | +11.8% | tweet ↗ |
| 2026-10-12 | @PrismMarketView | +0.15 | Reports an upcoming interim Phase 3 presentation and planned supplemental BLA submission, with no results disclosed. | +11.8% | tweet ↗ |
| 2026-10-11 | @PolarizingLit | +0.20 | Self-deprecatingly describes conviction in five speculative stocks. | +7.4% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.